MON-LB054 Activity of Prolactin Receptor Antagonist-Rapamycin Conjugate in Glioblastoma Multiform
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the Endocrine Society"
DOI: 10.1210/js.2019-mon-lb054
Abstract: Abstract Background: Glioblastoma multiform (GBM) is the most common and aggressive primary brain tumor in humans, accounting for approximately 12-15% of all intracranial tumors, with a median survival of 15 months. Although GBM is not… read more here.
Keywords: rapamycin; antagonist rapamycin; glioblastoma multiform; activity ... See more keywords
Integrative Analyses and Verification of the Expression and Prognostic Significance for RCN1 in Glioblastoma Multiforme
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Molecular Biosciences"
DOI: 10.3389/fmolb.2021.736947
Abstract: Glioblastoma multiform is a lethal primary brain tumor derived from astrocytic, with a poor prognosis in adults. Reticulocalbin-1 (RCN1) is a calcium-binding protein, dysregulation of which contributes to tumorigenesis and progression in various cancers. The… read more here.
Keywords: glioblastoma; glioblastoma multiform; glioblastoma multiforme; rcn1 ... See more keywords
Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.939570
Abstract: Glioblastoma multiform is the most aggressive primary type of brain tumor, representing 54% of all gliomas. The average life span for glioblastoma multiform is around 14–15 months instead of treatment. The current treatment for glioblastoma… read more here.
Keywords: parp; development; glioblastoma multiform; parp inhibitors ... See more keywords